The Pharma Data

SEPTEMBER 21, 2020

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics.

Therapies 52

Therapies Cell Biology Licensing Licensing 52

Drug Target Review

APRIL 9, 2024

Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 64

RNA Cell Biology Clinical Development Disease 64

The Pharma Data

DECEMBER 1, 2020

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. About Innate Pharma: Innate Pharma S.A.

Cell Biology 52

Cell Biology Clinical Trials Production Licensing 52

The Pharma Data

MARCH 11, 2021

Second, the biorevolution is driving innovation in all of Bayer’s divisions – with major progress in cell biology, gene editing and data science. Last year alone, the company concluded more than 25 collaboration and licensing agreements and acquisitions in its Pharmaceuticals Division.

Science 52

Science Pharmaceuticals Licensing Licensing 52

Codon

APRIL 2, 2023

An open-source FACS automation system for high-throughput cell biology. Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms. Academic licenses had lower royalty rates, deal sizes, and pre-commercial payments compared to corporate licenses.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JANUARY 4, 2021

This leads to activation and specific tumor-killing and cytokine secretion by NK cells, an immune cell population representing a significant proportion of all cytotoxic lymphocytes in the body.

Drugs 40

Drugs Cell Biology Pharmacokinetics Clinical Trials 40

The Pharma Data

OCTOBER 22, 2020

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. About Innate Pharma: Innate Pharma S.A.

Clinical Trials 40

Clinical Trials Trials Cell Biology Production 40